Humanoid Surgeons Scrub In: Is This the Day Intuitive Surgical Gets Nervous Or Check In? -( $ASXC $ISRG $MDT $NVDA ) by John F. Heerdink, Jr. 5 hours ago Read more The Pivot Point: How Modular Medical (NASDAQ: MODD) Is Betting on the 70% of Diabetics That Big Insulin Forgot -( $MODD $PODD $MDT $TNDM ) by John F. Heerdink, Jr. 9 hours ago Read more Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI ) by John F. Heerdink, Jr. 1 day ago Read more Doctors Get Scribes, Models Get Data, Investors Get Upside?: Inside DOCS, AMWL, SMWB, META and NVDA’s AI Flywheel by John F. Heerdink, Jr. 1 day ago Read more Trump Goes Down Under: How Aussie-Style Retirements Could Supercharge Wall Street’s Long Game -( $AMWL $MODD ) by John F. Heerdink, Jr. 2 days ago Read more Biotech Sizzles While Beef Soars: Why Investors Are Buying Labs, Not Ribeyes -( $AMWL $EPRX $MODD $XBI ) by John F. Heerdink, Jr. 4 days ago Read more Eupraxia’s Board Gets A Major Upgrade: Why EPRX Is Suddenly On Grown‑Up Biotech Lists -( $EPRX $IBB $SNY $XBI ) by John F. Heerdink, Jr. July 7, 2026 Read more From Couch to $50 Copay: Medicare’s Bridge Program and the Long‑Only Case for Obesity as a Chronic‑Care Asset Class -( $LLY MODD $NVO ) by John F. Heerdink, Jr. July 5, 2026 Read more The Immune System Strikes Back: Why Biogen’s M&A Spree and Eupraxia’s Trial Progress Deserve a Place On Your Radar -( $APLS $BIIB $EPRX ) by John F. Heerdink, Jr. July 3, 2026 Read more When Simplicity Becomes a Moat: How Modular Medical’s Pivot Pump Could Reprice Diabetes Convenience -( $ABT $MODD $LLY ) by John F. Heerdink, Jr. July 1, 2026 Read more Read more
